Patient-reported Impact of Axial Spondyloarthritis on Working Life: Results from the EMAS survey

Psoriatic Arthritis

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

Health Qual Life Outcomes.

Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, Lim I, Eder L, Richette P, Weng MY, Queiro Silva R, Fallon L

doi: 10.1186/s12955-020-01422-z.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Rheumatology (Oxford).

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A

doi: 10.1093/rheumatology/kex174.

Spinal Disorders

Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial

Semin Arthritis Rheum.

Molto A, Gossec L, Poiraudeau S, Claudepierre P, Soubrier M, Fayet F, Wendling D, Gaudin P, Dernis E, Guis S, Pouplin S, Ruyssen A, Chales G, Mariette X, Beauvais C, Combe B, Flipo RM, Richette P, Chary-Valckenaere I, Saraux A, Sibilia J, Schaeverbeke T, Dougados M

doi: 10.1016/j.semarthrit.2020.05.012.

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

Psoriatic Arthritis

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Rheumatology (Oxford).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD

doi: 10.1093/

Further Publications Rheumatology

How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort

Rheumatology (Oxford)

Nikiphorou E, Boonen A, Fautrel B, Richette P, Landewé R, van der Heijde D, Ramiro S

doi: 10.1093/rheumatology/keab607

Psoriatic ArthritisSpinal Disorders

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

Rheumatology (Oxford).

Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, Santos MJ, Koca SS, Askling J, Rotar Z, Gudbjornsson B, Codreanu C, Loft AG, Kristianslund EK, Mann HF, Ciurea A, Eklund KK, Vieira-Sousa E, Yazici A, Jacobsson L, Tomšič M, Löve TJ, Ionescu R, van der Horst-Bruinsma IE, Iannone F, Pombo-Suarez M, Jones GT, Hyldstrup LH, Krogh NS, Hetland ML, Østergaard M

doi: 10.1093/rheumatology/kez656.

Psoriasis

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial

Adv Ther

Gottlieb AB, Warren RB, Augustin M, Garcia L, Cioffi C, Peterson L, Pelligra C, Ciaravino V

doi: 10.1007/s12325-021-01836-1

Further Publications Rheumatology

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Ann Rheum Dis

Wei JC, Kim TH, Kishimoto M, Ogusu N, Jeong H, Kobayashi S, 4827-006 study group.

doi: 10.1136/annrheumdis-2020-219406

Related content

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial